Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
Sen. Mark Kelly champions the PAIN Act to improve seniors' access to non-opioid pain treatments under Medicare.
On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...
The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.
AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...
Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization ---- Adds novel, high-capacity, local-delivery platform ...
Chronic pain is complex and difficult to treat. Prescribing opioid pain medications has become controversial but may help ...
9d
GlobalData on MSNGLP-1RAs and opioid use disorder: a new frontier in addiction treatmentWhile medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...
PARSIPPANY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood ...
On February 17, VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj., was approved on December 12, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results